Three human papillomavirus (HPV) vaccines are available:
Quadrivalent vaccine (Gardasil) targets HPV types 6, 11, 16, and 18.
Nonavalent vaccine (Gardasil 9) targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
Bivalent vaccine (Cervarix) targets HPV types 16 and 18.
HPV types 16 and 18 cause approximately 70 percent of all cervical cancers and nearly 90 percent of anal cancers, as well as a significant proportion of oropharyngeal cancer, vulvar and vaginal cancer, and penile cancer.
Quadrivalent and 9-valent vaccine also protect against anogenital warts, 90 percent of which are caused by HPV types 6 and 11.
Target age group :
As per ACIP / CDC/ ACS:
For females – Routine immunization should be offered at 11 to 12 years of age, but can be administered starting at 9 years.
Catch-up vaccination should be offered for females aged 13 to 26 years who have not been previously vaccinated.
For males – Routine immunization should be offered at 11 to 12 years of age, but can be administered starting at 9 years.
Catch-up vaccination should be offered for males between the ages of 13 to 21 who have not been previously vaccinated.
For men who have sex with men (MSM) and immunocompromised males, catch-up vaccination should be offered up to age 26.
Dosing schedule:
For individuals starting any HPV vaccine series when they are younger than 15 years old, 2 – dose schedule ( 0 & 6 months ) is recommended suggest.
For individuals starting any HPV vaccine series at 15 years and older, the HPV vaccine is administered in three doses at 0, at 1 to 2 months, and at 6 months. Immunocompromised patients should also receive a three-dose series.
Excellent antibody responses have been reported following immunization with the 9-valent, quadrivalent, and bivalent vaccines, with seroconversion rates of 93 to 100 percent in females and 99 to 100 percent in males
HPV test is not required prior to vaccination.
As per FOGSI & IAP : Can be given from 9 to 45 years of age